Bell G D, Lewis B, Petrie A, Dowling R H
Br Med J. 1973 Sep 8;3(5879):520-3. doi: 10.1136/bmj.3.5879.520.
Hypercholesterolaemia has been predicted as a possible complication of chenodeoxycholic acid treatment for gall stones. To exclude this, fasting serum lipids were measured in patients with stones before and at monthly intervals for six months after starting chenodeoxycholic acid. Before treatment half of a group of 36 patients with presumed cholesterol gall stones had serum cholesterol levels exceeding 260 mg/100 ml or serum triglyceride values greater than 160 mg/100 ml or both; these lipid levels were significantly greater than those in control subjects matched for age and sex. Treatment with chenodeoxycholic acid (0.5-1.5 g/day by mouth) did not change serum cholesterol levels but did significantly reduce serum triglyceride concentrations from a pretreatment level of 118 (+/- S.E. of mean 11.7) mg/100 ml to 95 (+/- 7.2) mg/100 ml after six months of therapy. The mechanism of this triglyceride-lowering action of chenodeoxycholic acid is not known, but it may have therapeutic value in patients with hypertriglyceridaemia.
高胆固醇血症被预测为鹅去氧胆酸治疗胆结石可能出现的并发症。为排除这种情况,对胆结石患者在开始服用鹅去氧胆酸之前及之后的六个月内每月测量空腹血脂。治疗前,一组36例疑似胆固醇结石患者中有一半的血清胆固醇水平超过260mg/100ml,或血清甘油三酯值大于160mg/100ml,或两者兼有;这些血脂水平显著高于年龄和性别相匹配的对照组。口服鹅去氧胆酸(0.5 - 1.5g/天)治疗并未改变血清胆固醇水平,但在治疗六个月后,血清甘油三酯浓度从治疗前的118(±平均标准误11.7)mg/100ml显著降至95(±7.2)mg/100ml。鹅去氧胆酸这种降低甘油三酯作用的机制尚不清楚,但它可能对高甘油三酯血症患者具有治疗价值。